"By engineering a common probiotic bacterium to act as a living drug factory within tumors, researchers are pioneering a novel approach to combat notoriously difficult-to-treat pancreatic cancers, offering a glimpse into a future where ‘bugs as drugs’ could revolutionize cancer therapy."
A groundbreaking study published in Science Advances details the development of a genetically modified strain of Bifidobacterium longum, a bacterium commonly found in the human gut and in probiotic supplements, which has demonstrated significant potential in targeting and suppressing pancreatic tumors in preclinical models. This innovative strategy leverages the unique biological characteristics of bacteria to deliver therapeutic agents directly to cancerous sites, overcoming key limitations of conventional cancer treatments. The research team at the University of Chicago has engineered this bacterium, dubbed BifidoSumIL-2, to act as a localized producer of a potent anti-cancer compound, offering a novel "bugs as drugs" approach to oncological therapy.
Pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer, presents a formidable challenge to medical science. Often characterized as a "cold tumor," it possesses a dense, resistant microenvironment that effectively shields it from immune system surveillance and impedes the penetration of conventional chemotherapeutic agents. This recalcitrance is further compounded by a hypoxic (low-oxygen) tumor core, which not only hinders drug efficacy but also plays a crucial role in the tumor’s survival and progression. The University of Chicago team has ingeniously harnessed this hypoxic environment as a natural targeting mechanism. Bifidobacterium longum is an obligate anaerobe, meaning it thrives in oxygen-depleted conditions and cannot survive in oxygen-rich healthy tissues. When introduced into the bloodstream of test animals, BifidoSumIL-2 is naturally eliminated from healthy organs while preferentially colonizing the hypoxic interior of solid tumors, where it can safely reside and replicate. This biological selectivity eliminates the need for complex drug delivery systems or invasive procedures, allowing the tumor’s own defenses to guide the therapeutic agent.
The engineering of Bifidobacterium longum involved two critical modifications. Firstly, the bacterium was endowed with the genetic machinery to produce Interleukin-2 (IL-2), a powerful immune-stimulating cytokine that has been explored in cancer therapy for decades. However, traditional administration of IL-2 has been hampered by significant systemic toxicity, a short half-life, and its tendency to activate regulatory T cells, which paradoxically dampen anti-tumor immune responses, alongside the desired effector T cells. To circumvent these issues, the researchers utilized protein engineering to create SumIL-2, a modified version of IL-2 designed to preferentially stimulate cancer-fighting T cells while minimizing the activation of suppressive regulatory T cells.
Secondly, the researchers addressed the delivery challenge by transforming the bacterium itself into a localized drug factory. Instead of flooding the entire body with IL-2 and risking widespread side effects, the engineered BifidoSumIL-2 strain colonizes the tumor and continuously secretes SumIL-2 directly at the tumor site. This localized production ensures a higher concentration of the therapeutic agent where it is most needed, while significantly reducing systemic exposure and potential toxicity. This represents a paradigm shift in drug development, moving towards "living therapeutics" or "bugs as drugs," where the delivery vehicle not only carries the payload but also replicates, persists, and manufactures its therapeutic cargo in situ.
The effectiveness of this engineered bacterium was demonstrated in various preclinical models. In subcutaneous tumor models, systemically administered BifidoSumIL-2 was observed to selectively colonize tumors and suppress their growth. This anti-tumor effect was found to be dependent on both the STING pathway, an innate immune sensor, and the action of T cells, highlighting the immune-mediated nature of the therapy. More critically, in orthotopic models, which more closely mimic the anatomical and microenvironmental conditions of human pancreatic cancer by growing tumors within the pancreas, BifidoSumIL-2 demonstrated its ability to suppress tumor growth by reshaping the tumor microenvironment and enhancing the activity of CD8+ T cells, the primary cancer-killing immune cells.
Perhaps the most clinically relevant findings emerged from combination studies. When BifidoSumIL-2 was administered alongside standard cancer treatments such as chemotherapy, radiotherapy, or anti-PD-L1 immunotherapy (checkpoint blockade), the anti-tumor effects were significantly amplified compared to the bacterium alone. This synergistic effect is particularly promising, as it suggests that this engineered bacterium could serve as an adjuvant therapy, enhancing the efficacy of existing treatments in tumors that are currently resistant to them. The development path envisioned by the researchers does not involve replacing standard care but rather augmenting it to overcome treatment resistance in challenging cancers.
It is important to note that Bifidobacterium longum is not the only bacterial species attracting attention in pancreatic cancer research. A separate study published in Cell Host & Microbe reported that the same species can colonize pancreatic tumors and even invade cancer cells, eliciting anti-tumor effects through a rapamycin-triggered process involving bacterial neoantigen presentation. This underscores the growing recognition of the complex interplay between the gut microbiome and cancer, and the potential for specific bacterial species to influence tumor behavior. However, research also indicates that not all bacteria found within pancreatic tumors are beneficial, highlighting the need for precise engineering and careful selection of therapeutic strains.
Despite the promising preclinical results, a significant distance remains between these findings in mice and clinical application in humans. Every caveat inherent in preclinical cancer research applies here, with additional concerns specific to the use of live, replicating bacteria in patients. Mouse models of tumor immunology, while valuable, are notoriously poor predictors of human response, and pancreatic cancer is a prime example of this disconnect. The deliberate introduction of live bacteria into the bloodstream of individuals with compromised immune systems raises critical safety questions that mouse experiments cannot fully address. These include the risk of sepsis, challenges in biocontainment, ensuring the bacteria remain confined to the tumor site, and potential complications if patients require antibiotics for unrelated infections. Furthermore, clinical safety, the long-term durability of the treatment, and the optimal delivery route all remain undetermined.
Another factor complicating the attribution of results is that Bifidobacterium species are known to possess independent effects on anti-tumor immunity, even without genetic modification. This makes it challenging to definitively attribute the observed anti-tumor effects solely to the engineered SumIL-2 payload. The research was supported by grants from the Ludwig Foundation and the National Institutes of Health.
For individuals currently battling pancreatic cancer, the actionable advice remains focused on established clinical practices. Comprehensive molecular profiling of the tumor is crucial for identifying eligibility for existing targeted therapies and for participation in open clinical trials. These diagnostic tests are readily available and should be discussed with a treating oncologist. Treatment decisions should always be made in consultation with a medical professional, and patients should not alter their current treatment regimens in anticipation of experimental agents.
The key questions answered by this research highlight the transformative potential of this approach:
What is BifidoSumIL-2?
BifidoSumIL-2 is a genetically engineered strain of the probiotic bacterium Bifidobacterium longum. It has been modified to continuously secrete SumIL-2, a specialized variant of Interleukin-2, once it successfully colonizes a tumor.
Why does the bacterium go to the tumor?
Bifidobacterium longum is an obligate anaerobe, meaning it requires an oxygen-depleted environment to survive and proliferate. Solid tumors, particularly pancreatic adenocarcinomas, are characterized by hypoxic interiors. This low-oxygen environment makes tumors a uniquely suitable habitat for the bacterium, allowing it to selectively colonize and replicate within cancerous tissues while being cleared from oxygen-rich healthy organs.
Why not just give IL-2 as a drug?
Administering Interleukin-2 (IL-2) systemically at doses effective against cancer carries a high risk of significant toxicity. The drug also has a short half-life, meaning it is quickly cleared from the body. Moreover, IL-2 can activate regulatory T cells, which suppress anti-tumor immune responses, counteracting the desired therapeutic effect. The engineered BifidoSumIL-2 system addresses these issues by delivering a modified IL-2 (SumIL-2) locally and continuously within the tumor.
Was this tested in humans?
No, this research has not yet been tested in humans. All reported results are derived from studies conducted in mice, utilizing both subcutaneous and orthotopic models of pancreatic cancer. There are currently no clinical trials involving BifidoSumIL-2, and it is not available for patient use.
Did it work better with other treatments?
Yes, the therapeutic effects of BifidoSumIL-2 were significantly enhanced when used in combination with chemotherapy, radiotherapy, or checkpoint blockade immunotherapy. These combined approaches demonstrated stronger anti-tumor activity than the bacterium administered alone, suggesting its potential as an adjunct therapy to improve outcomes in patients resistant to standard treatments.
What should a patient do with this information?
For patients with pancreatic cancer, the immediate actionable step is not related to this experimental therapy. Instead, patients should focus on comprehensive molecular profiling of their tumor. This testing can identify eligibility for existing targeted therapies and clinical trials. Patients should discuss these options and any treatment decisions with their oncologist, and under no circumstances should they alter their current treatment regimen based on this preclinical research.
